Retinal Ganglion Cell Function and Perfusion following Intraocular Pressure Reduction with Preservative-Free Latanoprost in Patients with Glaucoma and Ocular Hypertension
- PMID: 38592025
- PMCID: PMC10931696
- DOI: 10.3390/jcm13051226
Retinal Ganglion Cell Function and Perfusion following Intraocular Pressure Reduction with Preservative-Free Latanoprost in Patients with Glaucoma and Ocular Hypertension
Abstract
(1) Background: Given the global prevalence of glaucoma and the crucial role of intraocular pressure (IOP) reduction in the management of the disease, understanding the immediate effects on retinal structure and function is essential. (2) Methods: This study aimed to assess the effects of preservative-free latanoprost on morphological and functional parameters in treatment-naïve patients with ocular hypertension and open-angle glaucoma. (3) Results: This study showed a significant reduction in IOP by an average of 30.6% after treatment with preservative-free latanoprost. Despite the significant reduction in IOP, no statistically significant changes were observed in the electroretinogram (ERG) nor the optical coherence tomography/angiography (OCT/OCTA) parameters compared to baseline. An exploration of the correlation between IOP changes and various parameters revealed a significant association solely with the macular IPL/INL plexus vessel density (VD) measured with OCTA. (4) Conclusions: This finding suggests a possible association between IOP reduction and changes in the macular microcirculation and provides valuable insights into the differential effects of latanoprost. Acknowledging the study limitations, this study emphasizes the need for larger, longer-term investigations to comprehensively assess the sustained effects of preservative-free latanoprost on both IOP and retinal parameters. In addition, exploring systemic factors and conducting subgroup analyses could improve personalized approaches to glaucoma treatment.
Keywords: electroretinogram; optical coherence tomography; optical coherence tomography angiography; preservative-free latanoprost; retinal ganglion cell.
Conflict of interest statement
B.C. is a consultant and speaker for Thea and Santen. The other authors declare no conflicts of interest.
Figures
Similar articles
-
Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.Curr Med Res Opin. 2016 Aug;32(8):1457-63. doi: 10.1080/03007995.2016.1202818. Epub 2016 Jun 25. Curr Med Res Opin. 2016. PMID: 27310103 Clinical Trial.
-
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.Adv Ther. 2022 Aug;39(8):3501-3521. doi: 10.1007/s12325-022-02166-6. Epub 2022 May 7. Adv Ther. 2022. PMID: 35524840 Free PMC article.
-
Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.Adv Ther. 2021 Jun;38(6):3019-3031. doi: 10.1007/s12325-021-01731-9. Epub 2021 Apr 23. Adv Ther. 2021. PMID: 33891269 Free PMC article.
-
[A challenge to primary open-angle glaucoma including normal-pressure. Clinical problems and their scientific solution].Nippon Ganka Gakkai Zasshi. 2012 Mar;116(3):233-67; discussion 268. Nippon Ganka Gakkai Zasshi. 2012. PMID: 22568103 Review. Japanese.
-
Latanoprost : an update of its use in glaucoma and ocular hypertension.Drugs Aging. 2003;20(8):597-630. doi: 10.2165/00002512-200320080-00005. Drugs Aging. 2003. PMID: 12795627 Review.
References
-
- Bourne R.R., Taylor H.R., Flaxman S.R., Keeffe J., Leasher J., Naidoo K., Pesudovs K., White R.A., Wong T.Y., Resnikoff S., et al. Number of People Blind or Visually Impaired by Glaucoma Worldwide and in World Regions 1990–2010: A Meta-Analysis. PLoS ONE. 2016;11:e0162229. doi: 10.1371/journal.pone.0162229. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources